An Open-label, Multicenter, Dose-escalation, Phase I Study to Evaluate Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281, an Immunocytokine Consisting of Interleukin 2 Variant (IL-2v) Targeting Fibroblast Activation Protein-Alpha (FAP), in Patients With Advanced and/or Metastatic Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 12 May 2017
At a glance
- Drugs RO 6874281 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Roche
- 13 Mar 2017 Planned End Date changed from 31 Mar 2019 to 28 May 2019.
- 13 Mar 2017 Planned primary completion date changed from 31 Mar 2019 to 28 May 2019.
- 01 Sep 2016 Planned End Date changed from 1 May 2017 to 1 Mar 2019.